SCHEMBL241535

SCHEMBL241535

Cc1c(-c2ccccn2)nc2cccc(F)c2c1Nc1nc(N2CCOCC2)ncc1-c1ccc(OC(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.47
PIK3CA P42336 9/20 0.45
PIK3CB P42338 1/20 0.43
CASP1 P29466 5/20 0.36
CASP7 P55210 5/20 0.36
USP2 O75604 4/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
TSHR P16473 2/20 0.36
CYP1A2 P05177 5/20 0.35
HIF1A Q16665 2/20 0.35
CCNE1 P24864 1/20 0.35
CDK2 P24941 1/20 0.35
CDK5 Q00535 1/20 0.35
ALDH1A1 P00352 5/20 0.35
HSD17B10 Q99714 3/20 0.35
AOC3 Q16853 1/20 0.35
LMNA P02545 1/20 0.35
KDM4E B2RXH2 1/20 0.34
HTR2A P28223 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244881 0.92 PIK3CD (0.58) PIK3CDPIK3CAPIK3CB
SCHEMBL247334 0.80 PIK3CD (0.61) PIK3CDPIK3CAPIK3CB
SCHEMBL243055 0.78 PIK3CD (0.56) PIK3CDPIK3CAPIK3CBCASP1CASP7
SCHEMBL2713485 0.76 PIK3CD (0.81) PIK3CDPIK3CAPIK3CB
SCHEMBL241524 0.75 PIK3CD (0.54) PIK3CDPIK3CAPIK3CBUSP2TSHR
SCHEMBL247664 0.74 PIK3CD (0.58) PIK3CDPIK3CAPIK3CB
SCHEMBL247262 0.73 PIK3CD (0.50) PIK3CDPIK3CAPIK3CBMAPK1
SCHEMBL27866911 0.73 PIK3CA (0.58) PIK3CDPIK3CAPIK3CBCCNE1CDK2
SCHEMBL2715834 0.72 PIK3CD (0.65) PIK3CDPIK3CAPIK3CB
SCHEMBL27883215 0.72 PIK3CD (0.59) PIK3CDPIK3CAPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2588473-A1 NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS Amgen Inc. (US) 2013-05-08 EP disclosed
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. 2013-03-28 US disclosed
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. 2013-03-28 US disclosed
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. 2013-03-28 US disclosed
WO-2012003264-A1 NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS AMGEN INC. (US) 2012-01-05 WO disclosed
WO-2012003264-A1 NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS AS PIK3 -DELTA INHIBITORS AMGEN INC. (US) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079342-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, BCL9, MALT1 PIK3CD 25/4885PIK3CA 26/4885PIK3CB 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.